Altogether, these results indicate that treatment with CL429, a TLR2 and NOD2 agonist, leads to increased production of cytokines and antibacterial mediators ex vivo, in the peritoneal cavity, the bone marrow and the spleen, which are remote from the site of infection. The gene discussed is TLR2; the disease is infection.